[go: up one dir, main page]

WO2023108172A3 - Analogs of 4-substituted-2,5-dimethoxyamphetamine - Google Patents

Analogs of 4-substituted-2,5-dimethoxyamphetamine Download PDF

Info

Publication number
WO2023108172A3
WO2023108172A3 PCT/US2022/081364 US2022081364W WO2023108172A3 WO 2023108172 A3 WO2023108172 A3 WO 2023108172A3 US 2022081364 W US2022081364 W US 2022081364W WO 2023108172 A3 WO2023108172 A3 WO 2023108172A3
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
deuterium
dimethoxyamphetamine
analogs
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/081364
Other languages
French (fr)
Other versions
WO2023108172A2 (en
Inventor
Matthew Duncton
Samuel CLARK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terran Biosciences Inc
Original Assignee
Terran Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terran Biosciences Inc filed Critical Terran Biosciences Inc
Publication of WO2023108172A2 publication Critical patent/WO2023108172A2/en
Publication of WO2023108172A3 publication Critical patent/WO2023108172A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed herein are compounds of the formula wherein R1 is methyl; R2 is selected from hydrogen, deuterium, and methyl, or R1 and R2 together with the atom to which they are attached form a cyclopropyl; R3 and R4 independently are selected from hydrogen, deuterium, and methyl; R5 is halo or methyl; at least one of R1, R2, R3, R4, and R5, comprise deuterium or tritium; and Y1, Y2, Y3, Y4, Y5, and Y6 is hydrogen or deuterium. as well as methods for their use in treating neurologic and brain disorders.
PCT/US2022/081364 2021-12-11 2022-12-12 Analogs of 4-substituted-2,5-dimethoxyamphetamine Ceased WO2023108172A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163288585P 2021-12-11 2021-12-11
US202163288584P 2021-12-11 2021-12-11
US63/288,584 2021-12-11
US63/288,585 2021-12-11

Publications (2)

Publication Number Publication Date
WO2023108172A2 WO2023108172A2 (en) 2023-06-15
WO2023108172A3 true WO2023108172A3 (en) 2023-08-03

Family

ID=86731352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/081364 Ceased WO2023108172A2 (en) 2021-12-11 2022-12-12 Analogs of 4-substituted-2,5-dimethoxyamphetamine

Country Status (1)

Country Link
WO (1) WO2023108172A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3239565A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103979A1 (en) * 2005-03-15 2006-10-05 Showa Denko K.K. (meth)acryloyl group-containing aromatic isocyanate compound and production process thereof
WO2018039642A1 (en) * 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschränkt) Compositions and methods thereof
US20180243241A1 (en) * 2017-02-24 2018-08-30 Chemapotheca, Llc Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103979A1 (en) * 2005-03-15 2006-10-05 Showa Denko K.K. (meth)acryloyl group-containing aromatic isocyanate compound and production process thereof
WO2018039642A1 (en) * 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschränkt) Compositions and methods thereof
US20180243241A1 (en) * 2017-02-24 2018-08-30 Chemapotheca, Llc Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND ANONYMOUS : "2-(2-Aminopropyl)-5fluorobenzene-1,4-diol", XP093083694, retrieved from PUBCHEM *
TIMMINS, G., S.: "Deuterated Drugs: where are we now?", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 24, no. 10, 29 July 2014 (2014-07-29), pages 1 - 9, XP055132523, DOI: 10.1517/13543776.2014.943184 *

Also Published As

Publication number Publication date
WO2023108172A2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
MX2022009526A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders.
PH12016501822A1 (en) Cyclopropaneamine compound
MX2009008781A (en) Spirocyclic cyclohexane derivatives.
UA98098C2 (en) Pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
ECSP099324A (en) NEW DERIVATIVES OF AMINOPIRIMIDINE AS PLK1 INHIBITORS
EA017914B8 (en) 1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MODULATORS OF mGluR2-RECEPTORS
MX2010002537A (en) 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones.
TW200639158A (en) New compounds with therapeutic effect
NO20092415L (en) Heteromonocyclic compound and its use
MX2009009422A (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators.
MX2014015501A (en) Fungicidal heterocyclic carboxamides.
MX2015012008A (en) Novel inhibitor compounds of phosphodiesterase type 10a.
JO3098B1 (en) Diphenyl-pyrazole pyridine compounds and their preparation and use as nuclear receptor modifiers
CU23926B1 (en) DERIVATIVE OF OXOPIRAZINE AND HERBICIDE
PH12018500533A1 (en) Pyrazolyl-substituted heteroaryls and their use as medicaments
MX2010001486A (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists.
MX2015012389A (en) Novel inhibitor compounds of phosphodiesterase type 10a.
AR040489A1 (en) COMPOUNDS DERIVED FROM 3-PHENYL-PROPIONAMIDE, 3-PHENYL-ACRYLAMIDE AND 3-PHENYL-PROPINAMID, ITS USE FOR THE PREPARATION OF MEDICINES, A PROCESS TO PREPARE THE COMPOUNDS AND MEDICINES CONTAINING THEM
WO2023108172A3 (en) Analogs of 4-substituted-2,5-dimethoxyamphetamine
PH12018502457B1 (en) Treatment for parkinson's disease
PH12013502110A1 (en) Method for promoting plant growth
MX2009010461A (en) Quinolines and their therapeutic use.
PE20141168A1 (en) DERIVATIVES OF PYRAZOLIDIN-3-ONA
EA201390374A1 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DISORDERS CAUSED BY FACILITATED BY NEUROTREMISSION OF SEROTONIN, NOREPINEFRIN OR DOPAMINE
WO2006003013A3 (en) NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17β-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22905452

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22905452

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 30/09/2024).

122 Ep: pct application non-entry in european phase

Ref document number: 22905452

Country of ref document: EP

Kind code of ref document: A2